From Breakthrough to Blockbuster: The Business of Biotechnology Drakeman Donald L.
From Breakthrough to Blockbuster: The Business of Biotechnology Drakeman Donald L. How could a large collection of small companies, most with fewer than 50 employees, rise to compete with Big Pharma,…
Specifikacia From Breakthrough to Blockbuster: The Business of Biotechnology Drakeman Donald L.
From Breakthrough to Blockbuster: The Business of Biotechnology Drakeman Donald L.
How could a large collection of small companies, most with fewer than 50 employees, rise to compete with Big Pharma, one of the world's most breathtakingly expensive and highly regulated industries?Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources.Biotech companies have met the challenge by creating nearly 40% more of the most important treatments for previously unmet medical needs. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world.
Moreover, they have done so with much lower overall costs.From Breakthrough to